Trestle Biotherapeutics
We are developing an implantable therapeutic tissue that will be surgically delivered to patients suffering from end stage renal disease. Upon implantation, this tissue will supplement the patient's renal function, eliminating their dependency on dialysis and improving their disease status. This has the potential to not only get these patients off dialysis - a significant impact for them and their families - but to greatly extend the time required before kidney transplantation is essential.
Y Combinator
yc-company-directory #4645We are developing an implantable therapeutic tissue that will be surgically delivered to patients suffering from end stage renal disease. Upon implantation, this tissue will supplement the patient's renal function, eliminating their dependency on dialysis and improving their disease status. This has the potential to not only get these patients off dialysis - a significant impact for them and their families - but to greatly extend the time required before kidney transplantation is essential.
sourceTrestle Biotherapeutics is classified as Healthcare from source descriptions and fund-directory context. Similar companies below are ranked from offline product facets and meaningful description overlap; category and source affiliation can only strengthen an existing product match. For lookup-created rows, the profile starts as pending enrichment until deeper source collection runs.
Local clusters rerank extracted product concepts and description terms. The generated graph remains the fallback for sparse descriptions: offline reciprocal product-similarity graph: extracted concepts + description terms + bounded category/affiliation boosts. Minimum fallback score: 0; max competitors: 6.
Companies similar to Trestle Biotherapeutics
A deterministic local cluster built from offline product facets and meaningful description terms. Category and selected-institution affiliation provide bounded tie-breaks. Open any peer to continue exploring its cluster.
Granza Bio
match 57Granza Bio is developing programmable therapeutics for the immune system. Our platform is built on the foundational discovery of immune “superkiller” attack particles — the natural ammunition used by cytotoxic immune cells to deliver potent, localized killing. By re-arming exhausted immune cells with newly programmed ammunition, Granza restores and enhances immune function. This approach enables a new class of treatments with the potential to transform diseases ranging from cancer to autoimmunit
shared product terms: develop, therapeutic, deliver, function; shared product theme: health and clinical care; same category: Healthcare; shared affiliation: Y Combinator
Relevium Medical
match 54Relevium Medical is developing an injectable gel for knee osteoarthritis. Approximately half the population will be diagnosed with this pain and progressive disease. Right now, patients have to undergo not only repeat injections to control their pain, but also have to take strong oral medications. Because the disease is progressive and only gets worse over time, many patients end up on highly addictive, high-dose opioids. To date, we have secured $3.7 million in non dilutive funding and complete
shared product terms: develop, disease, patient, but; shared product theme: health and clinical care; shared affiliation: Y Combinator
AudioFocus
match 53If we've learned anything in the last few years it's that spending time with our friends and family is essential to our well-being and happiness. Unfortunately, loud and noisy places like weddings and family gatherings hinder human connection, especially for the hearing impaired. In fact, the biggest unmet need in the entire hearing healthcare industry is hearing in noisy places. AudioFocus helps patients hear in these environments by only enhancing voices nearby the patients and ignoring ones f
shared extracted concepts: patients; shared product terms: time, essential, patient, these; shared product theme: health and clinical care; same category: Healthcare; shared affiliation: Y Combinator
Uncommon Therapeutics
match 49Our founder Noah, an experienced tech entrepreneur, was directly impacted by a severe genetic disease when his daughter was diagnosed with Rett Syndrome, a disease that afflicts 1 in 10,000 girls. Using an innovative polytherapy strategy, we’ve successfully improved her quality of life, and have designed new therapeutics that each could be worth billions and together could deliver a cure.
shared product terms: therapeutic, deliver, disease, improv; shared product theme: health and clinical care; same category: Healthcare; shared affiliation: Y Combinator
Hepatx
match 45Our vision is to provide regenerative medicine treatments that free patients from chronic liver disease and help usher in an era where diseased and damaged tissues can be repaired.
shared extracted concepts: patients; shared product terms: patient, disease, tissue; shared product theme: health and clinical care; same category: Healthcare; shared affiliation: Y Combinator
Rejuvenation Technologies Inc.
match 41Stanford-patented essential drug platform unlocks the healthspan, which is limited by short telomeres. Extends mouse lifespan by equivalent of 10 years in humans. Reverses 5-10 years of telomere shortening with one dose in one day. Preclinical efficacy in 4 organ systems including immune system. Entering clinical stage. CEO is Subject #1 in longevity trial. 50+ granted patents, 7 patent families. FDA INTERACT cleared. Raising $10M seed extension ($2M+ wired) to fund 3 investigator-initiated tria
shared product terms: essential, extend, stage, familie; shared product theme: health and clinical care; same category: Healthcare; shared affiliation: Y Combinator